Ustekinumab: “Real-world” outcomes and potential predictors of nonresponse in treatment-refractory Crohn’s disease

Table 6 Adverse events and infections in the study cohort listed according to the time of their occurrence

Therapy week	6	12	24	36	48
n	55	51	48	38	28
Adverse events and infections
Adverse events, n (%)	29 (52.7)	18 (35.3)	13 (27.1)	20 (52.6)	18 (64.3)
Sweat, n (%)	2 (3.6)	0	2 (4.2)	1 (2.6)	1 (3.6)
Dizziness, n (%)	0	1 (2.0)	0	1 (2.6)	2 (7.1)
Arthralgia, n (%)	6 (10.1)	6 (11.8)	4 (8.3)	5 (13.2)	2 (7.1)
Muscle cramps, n (%)	0	0	1 (2.1)	0	0
Loss of hair, n (%)	1 (1.8)	1 (2.0)	2 (4.2)	1 (2.6)	1 (3.6)
Skin itching, n (%)	2 (3.6)	3 (5.9)	1 (2.1)	1 (2.6)	0
Headaches, n (%)	4 (7.3)	2 (3.9)	1 (2.1)	2 (5.3)	2 (7.1)
Restlessness, n (%)	1 (1.8)	0	0	0	0
Fatigue, n (%)	3 (5.4)	2 (3.9)	0	2 (5.3)	1 (3.6)
Skin lesions, n (%)	3 (5.4)	1 (2.0)	1 (2.1)	4 (10.5)	2 (7.1)
Arterial hypertension, n (%)	1 (1.8)	0	0	2 (5.3)	1 (3.6)
Palpitations, n (%)	1 (1.8)	0	0	0	0
Eye problems, n (%)	1 (1.8)	1 (2.0)	1 (2.1)	0	0
Nausea, n (%)	2 (3.6)	1	0	1 (2.6)	0
Diarrhoea, n (%)	1 (1.8)	0	0	0	0
Vomiting, n (%)	1 (1.8)	0	0	0	0
Infections, n (%)	5 (9.1)	5 (9.8)	8 (16.7)	0	6 (21.4)
Tonsillitis, n (%)	1 (1.8)	0	0	0	0
Upper respiratory infection, n (%)	2 (3.6)	3 (5.9)	6 (12.5)	0	6 (21.4)
Enteritis (salmonella), n (%)	1 (1.8)	0	0	0	0
Vaginal infection, n (%)	1 (1.8)	0	0	0	0
Cytomegalovirus infection, n (%)	0	1 (2.0)	0	0	0
Otitis externa, n (%)	0	1 (2.0)	1 (2.1)	0	0
Fever of unknown origin, n (%)	0	0	1 (2.1)	0	0